2025-12-20 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the provided data.

**1) Return Rate Comparison (JNJ vs. VOO):**

*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops, manufactures, and sells pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 59.05%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:** -38.5 (Relative Divergence: 32.9)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. The negative divergence of -38.5 indicates that JNJ's return has lagged the S&P 500 considerably.  A relative divergence of 32.9 suggests that the current divergence is not near the worst it has been historically, but it's still on the lower end of the spectrum.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 336.6 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 310.9 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 351.4 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 379.2 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 412.2 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 425.6 |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3 | 377.6 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 348.4 |
| 2023-2025  | 30.0% | 79.6% | -35.0% | 0.1 | 497.2 |

**Analysis:**

*   **Alpha:** JNJ has consistently demonstrated negative alpha figures for the majority of the time, indicating underperformance relative to its risk-adjusted expected return. The most recent periods (2021-2025) show significantly negative alpha.
*   **Beta:** The beta values are generally low, suggesting that JNJ is less volatile than the overall market.
*   **CAGR:** Fluctuating CAGR values, with recent periods showing negative returns, reinforce the underperformance relative to the market.
*   **MDD:** Consistently high Maximum Drawdown (MDD) figures suggest significant potential for loss.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 206.37
*   **Previous Close:** 208.31
*   **Change:** -0.93
*   **5-day SMA:** 209.70
*   **20-day SMA:** 206.46
*   **60-day SMA:** 195.83

**Analysis:** The stock price has declined slightly recently. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, suggesting a potential upward trend, but the very recent negative change needs to be factored in.

**3) RSI, PPO, and Divergence:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 53.23 (Neutral)
*   **PPO:** -0.19 (Bearish, but close to zero)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent (20 days) Relative Divergence Change:** 10.2 (+) (Short-term rise)
*   **Expected Return (%):** -48.4 (Expected underperformance compared to the S&P 500 over the long term)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates a neutral market sentiment.
*   The PPO is slightly negative, suggesting a potential bearish trend, but it is hovering around zero, so not a strong signal.
*   The hybrid signal of a buy with zero cash suggests a bullish position overall but the "safe" description suggests limited upside.
*   The recent increase in relative divergence suggests a short-term upward trend, but the significantly negative expected return is a major concern.

**4) Recent News & Significant Events:**

*   **Talc Litigation:** Remains a significant issue.
*   **FDA Approvals and Analyst Targets:** Positive drivers in the short term.
*   **Institutional Buying (Czech National Bank):** Shows confidence in the stock.
*   **Market Rotation:**  Benefiting JNJ.
*   **Recent Decline:** Highlighted by Quiver Quantitative.

**Analysis:** The news is mixed. The talc litigation continues to cast a shadow, but positive news regarding FDA approvals, analyst targets, institutional buying, and market rotation provide some offsetting factors. The recent decline in the stock price needs to be watched.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price:** Avg: 209.29 / High: 240.00 / Low: 155.00

**Analysis:** Analysts, on average, have a "Buy" rating on JNJ. The average target price is slightly above the current price, suggesting potential upside. However, the wide range between the high and low target prices reflects uncertainty. No rating change.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-10-22 | 2.14  | 23.99 B$  |
| 2025-07-24 | 2.3   | 23.74 B$  |
| 2025-04-23 | 4.57  | 21.89 B$  |
| 2024-10-23 | 1.12  | 22.47 B$  |
| 2025-10-22 | 1.12  | 22.47 B$  |

**Analysis:** The data is a bit inconsistent - 2025-10-22 is listed twice with different values.
Assuming the latest entry for 2025-10-22 is correct:
*   Revenue has been relatively consistent over the last four quarters, showing steady performance.
*   EPS is showing a lot of fluctuation.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $23.99B   | 69.56%       |
| 2025-06-30   | $23.74B   | 67.87%       |
| 2025-03-31   | $21.89B   | 66.40%       |
| 2024-12-31   | $22.52B   | 68.35%       |
| 2024-09-30   | $22.47B   | 69.01%       |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-09-30   | $79.28B   | 6.50% |
| 2025-06-30   | $78.47B   | 7.06% |
| 2025-03-31   | $78.11B   | 14.08% |
| 2024-12-31   | $71.49B   | 4.80% |
| 2024-09-30   | $70.16B   | 3.84% |

**Analysis:**

*   Revenue: Stable and showing slight growth.
*   Profit Margin: Consistently high, indicating strong profitability and efficient operations.
*   Equity: Growing, showing financial stability.
*   ROE: Fluctuating, with a high point in Q1 2025, but trending downwards more recently, which requires attention.

**7) Comprehensive Analysis (Summary):**

Johnson & Johnson presents a mixed picture. While the company shows financial strength through stable revenue, high profit margins, and growing equity, it is currently underperforming the S&P 500 significantly. The negative alpha values and expected return indicate that this underperformance is likely to continue in the long term. The talc litigation remains a major overhang, creating uncertainty.

The short-term technical indicators are mixed, suggesting a possible short-term upward trend, but the longer-term outlook is concerning.  Analysts have a "Buy" rating, but the wide range in target prices reflects the inherent uncertainty. The fluctuating EPS data needs more clarity.  The declining ROE also needs to be further examined to determine the root cause.

**Overall Recommendation:**

Based on this data, a cautious approach is warranted. While JNJ possesses some positive attributes, the underperformance relative to the S&P 500 and the negative expected return are significant red flags. Current investors might want to consider re-evaluating their position. Potential investors should proceed with extreme caution and conduct further due diligence, especially regarding the talc litigation and the declining ROE. A focus on the company's plans to improve its competitive position and address the litigation risks is crucial before making any investment decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.